Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection

Interferon (IFN)-resistant hepatitis C virus strains limit efficacy of antiviral combination therapy in patients infected with genotypes 1 and 4. A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2008-01, Vol.13 (4), p.581-589
Main Authors: JESSNER, Wolfgang, GSCHWANTLER, Michael, FORMANN, Elisabeth, GURGUTA, Calin, WATKINS-RIEDEL, Thomas, WRBA, Friedrich, FERENCI, Peter
Format: Article
Language:English
Subjects:
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Biological and medical sciences
Drug Therapy, Combination
Female
Genotype
Hepacivirus - classification
Hepacivirus - drug effects
Hepacivirus - genetics
Hepacivirus - physiology
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Human viral diseases
Humans
Infectious diseases
Interferon-alpha - administration & dosage
Interferon-alpha - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - therapeutic use
Recombinant Proteins
Ribavirin - administration & dosage
Ribavirin - therapeutic use
RNA, Viral - blood
Time Factors
Treatment Outcome
Viral diseases
Viral hepatitis
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interferon (IFN)-resistant hepatitis C virus strains limit efficacy of antiviral combination therapy in patients infected with genotypes 1 and 4. A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV therapy in genotype 1 patients. Our aim was to investigate this approach in genotype 4 patients. Viral load was measured in 46 patients before and 24 h after 10 megaunits (MU) IFN-alpha2b, and before and during 2 weeks of daily 5 MU IFN-alpha2b administration. Thereafter, patients received 48 weeks combination therapy with either 180 microg PEG-IFN-alpha2a/week (n=33), 1.5 microg/kg PEG-IFN-alpha2b/week (n=7) or 5 MU IFN-alpha2b/2 days (n=6), along with 1-1.2g RBV/day. For prediction analysis the largest group (PEG-IFN-alpha2a) was evaluated only. Median 24 h log10 change after 10 MU IFN-alpha2b was 1.15 (range 0.08-2.48) and after 5 MU IFN-alpha2b was 0.81 (-0.12-2.22; P
ISSN:1359-6535
2040-2058
DOI:10.1177/135965350801300411